SPOTLIGHT: Say goodbye to Big Pharma's gilded age

Yes, generic competition has become something of a mantra in the drug industry. But we're going to start the chant again, because The Wall Street Journal took a close look at just how much revenue the industry will be lost over the next few years--and posits that Big Pharma's gilded age will soon be history. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.